Induced pluripotent stem cells (iPSCs) derived from adult somatic cells are becoming an increasingly important tool for developing novel cell therapies ... products at any hospital or clinic ...

Nor are traditional cell therapy laboratories necessarily resourced to receive, thaw, dose, and issue CGT products. Most hospitals understand that there is currently a shortage of trained ...

Autologous cell therapies that use a patient’s own cells pose the logistical challenge of shipping cells back and forth between a hospital and a manufacturing plant. These tasks drive up the ...

Mass General Brigham’s Gene and Cell Therapy Institute is partnering with Cambridge biotech Cellino to create the first in-hospital facility to manufacture patient-specific stem cells for ...